GRI Bio, Inc.
About GRI Bio, Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2021
- $0
- Net income
- -$12.0M
- Total assets
- $8.7M
- Market cap
- $3.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $12.0M
- Operating income
- -$12.0M
- Income tax
- $3.0K
- Net income
- -$12.0M
- EPS (basic)
- $-121.80
- EPS (diluted)
- $-121.80
Balance sheet
- Total assets
- $8.7M
- Current assets
- $8.6M
- Total liabilities
- $2.7M
- Current liabilities
- $2.6M
- Shareholders’ equity
- $6.0M
Cash flow
- Operating cash flow
- -$10.2M
- Investing cash flow
- -$3.0K
- Financing cash flow
- $13.4M
- Net cash flow
- $3.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.5M
- EPS (diluted)
- $-121.8
- Shares outstanding
- 1.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 24, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $12.0M in FY2021.
- Trading 96% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GRI Bio, Inc..
Write a review
News about GRI Bio, Inc.
News & sentiment via Polygon.io
